---
title: "CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295650820.md"
description: "H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CervoMed with a $25 price target, citing advancing dementia pipeline assets like neflamapimod and upcoming Phase 2a/3 data. Canaccord Genuity also maintained a Buy rating with an $18 target."
datetime: "2026-08-12T10:36:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295650820.md)
  - [en](https://longbridge.com/en/news/295650820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295650820.md)
generator: "portal-rs"
---

# CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on CervoMed and keeping the price target at $25.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Ram Selvaraju has given his Buy rating due to a combination of factors related to CervoMed’s lead asset, neflamapimod, and the company’s advancing clinical strategy. He highlights the imminent readouts from the Phase 2a study in non-fluent primary progressive aphasia, with near-term biomarker data and subsequent 24-week clinical results expected to further clarify the drug’s potential in frontotemporal dementia.

Selvaraju also emphasizes the upcoming pivotal development in dementia with Lewy bodies, supported by FDA-aligned trial design, extended patent protection through 2042, and favorable regulatory recognition via the U.K.’s ILAP Innovation Passport. He points to supportive Phase 2b data, including exposure–response and PK/PD analyses that underpin the selected Phase 3 dose, and maintains his conviction that these catalysts justify reiterating a Buy rating and an unchanged $25 price target.

Selvaraju covers the Healthcare sector, focusing on stocks such as CervoMed, Urogen Pharma, and Brainsway. According to TipRanks, Selvaraju has an average return of 25.5% and a 59.20% success rate on recommended stocks. 

In another report released on August 10, Canaccord Genuity also reiterated a Buy rating on the stock with a $18.00 price target.

### Related Stocks

- [CRVO.US](https://longbridge.com/en/quote/CRVO.US.md)
- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)
- [BWAY.US](https://longbridge.com/en/quote/BWAY.US.md)

## Related News & Research

- [CervoMed Q2 net loss lower than estimates as costs drop](https://longbridge.com/en/news/295400250.md)
- [07:56 ETVisiting Angels Sets $1 Million+ Fundraising Goal for 2026 Walk to End Alzheimer's](https://longbridge.com/en/news/297648151.md)
- [Analyst Maintains Buy Rating on Teladoc with Unchanged $10.50 Price Target Amid Strategic Transition and New CFO Appointment](https://longbridge.com/en/news/297585950.md)
- [08:53 ETSensi.AI Hosts "An Evening of Learnings with Sensi & Teepa Snow" for Senior Care Leaders](https://longbridge.com/en/news/297655729.md)
- [Barclays Reaffirms Their Buy Rating on Airbus Group SE (EADSF)](https://longbridge.com/en/news/297615153.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**